{"public_id":"cl_80576e7d4d77532f33dd322cfb77b906","status":"active","superseded_by_public_id":null,"corpus_id":10389450,"text":"MGUS progressed to multiple myeloma or other plasma-cell cancers in 115 of 1384 patients during 11,009 person-years of follow-up.","confidence":0.98,"paper":{"corpus_id":10389450,"title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","url":"https://sah.borca.ai/papers/10389450"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_16ba4fc847bb1b4fe7c432732a05cdec","name":"multiple myeloma","description":"A malignant plasma-cell cancer that can arise from a precursor monoclonal gammopathy.","types":["condition","cancer"],"url":"https://sah.borca.ai/concepts/co_16ba4fc847bb1b4fe7c432732a05cdec"},{"public_id":"co_6364ca9a2a7672d6318e6e4dedf77aa1","name":"plasma-cell cancer","description":"A malignant disease arising from plasma cells.","types":["condition","cancer"],"url":"https://sah.borca.ai/concepts/co_6364ca9a2a7672d6318e6e4dedf77aa1"},{"public_id":"co_8e536886c7f99d2174ed588c0a184caf","name":"monoclonal gammopathy of undetermined significance","description":"A plasma-cell disorder characterized by the presence of a monoclonal protein without overt malignant disease.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_8e536886c7f99d2174ed588c0a184caf"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_80576e7d4d77532f33dd322cfb77b906"}